Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;74(6):801-804.
doi: 10.1097/MPG.0000000000003425. Epub 2022 Feb 22.

The Impact of Compliance During Exclusive Enteral Nutrition on Faecal Calprotectin in Children With Crohn Disease

Shona Mckirdy  1 , Richard K Russell  2 , Vaios Svolos  1 , Konstantinos Gkikas  1 , Michael Logan  1 , Richard Hansen  3 , Konstantinos Gerasimidis  1
Affiliations
Free article

The Impact of Compliance During Exclusive Enteral Nutrition on Faecal Calprotectin in Children With Crohn Disease

Shona Mckirdy et al. J Pediatr Gastroenterol Nutr. .
Free article

Abstract

It remains unclear whether suboptimal response to exclusive enteral nutrition (EEN) in some children with Crohn disease (CD) is explained by poor compliance. The present study measured faecal gluten immunogenic peptides (GIP), a biomarker of gluten intake, in 45 children (3- 17 years) with CD, and explored associations with faecal calprotectin (FC) levels at 33 and 54 days of EEN. FC decreased in patients with undetectable GIP at both 33 and 54 days of EEN (mean decrease, 33 days: -743 mg/kg, 54 days: -1043 mg/kg, P < 0.001) but not in patients who had detectable levels. At EEN completion, patients with undetectable GIP had a lower FC by 717 mg/kg compared with patients with a positive GIP result (P = 0.042) and demonstrated a greater decline from baseline FC (-69% vs +5%, P = 0.011). Poorer response to EEN is explained in part by diminished compliance. Faecal GIP might be useful as proxy biomarker of EEN compliance.

PubMed Disclaimer

Conflict of interest statement

R.K.R. reports speaker's fees, travel support, advisory boards: Nestle, AbbVie, Celltrion & Pharmacosmos. K.G.'s PhD studentship was funded in partnership from the University of Glasgow and Nestle Health Science. M.L.'s PhD studentship was funded by the Engineering and Physical Sciences Research Council and Nestle Health Science. R.H. is supported by an NHS Research Scotland Career Researcher fellowship and has received speaker's fees, travel support and consultancy fees from 4D pharma. K.G. reports personal fees from Nutricia, research grants and personal fees from Nestle Health Science, personal fees from Dr Falk, Abbott, Servier, Mylan, and Baxter. S.M. and V.S. have no conflicts of interest to declare.

References

    1. Connors J, Basseri S, Grant A, et al. Exclusive enteral nutrition therapy in paediatric crohn's disease results in long-term avoidance of corticosteroids: results of a propensity-score matched cohort analysis. J Crohns Colitis 2017; 11:1063–1070.
    1. Gerasimidis K, Nikolaou CK, Edwards CA, et al. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 2011; 45:234–239.
    1. Logan M, Clark CM, Ijaz UZ, et al. The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction. Aliment Pharmacol Ther 2019; 50:664–674.
    1. Van Limbergen J, Haskett J, Griffiths AM, et al. Toward enteral nutrition for the treatment of pediatric Crohn disease in Canada: a workshop to identify barriers and enablers. Can J Gastroenterol Hepatol 2015; 29:351–356.
    1. Ho SSC, Day AS. Exclusive enteral nutrition in children with inflammatory bowel disease: physician perspectives and practice. JGH Open 2019; 3:148–153.

Publication types